SCHEMBL1779798

SCHEMBL1779798

CCOC(=O)n1nc(NC(=O)c2ccccc2NC(=O)c2cc(C)nn2CC)c2cc(C(=O)O)sc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.40
KMT2A Q03164 4/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
ALDH1A1 P00352 3/20 0.38
HSD17B10 Q99714 2/20 0.38
GAA P10253 1/20 0.38
SMYD3 Q9H7B4 1/20 0.38
FGFR1 P11362 3/20 0.37
MEN1 O00255 3/20 0.37
KDM4E B2RXH2 3/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
STING1 Q86WV6 4/20 0.36
TSHR P16473 1/20 0.36
TP53 P04637 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1780565 0.91 ALDH1A1 (0.40) KDRKMT2ANPC1RAB9AALDH1A1
SCHEMBL1781304 0.90 KDR (0.37) KDRKMT2ANPC1RAB9AALDH1A1
SCHEMBL1779872 0.86 KDR (0.37) KDRKMT2ANPC1RAB9AALDH1A1
SCHEMBL1778749 0.85 INSR (0.35)
SCHEMBL1778607 0.84 ALDH1A1 (0.38) KMT2ANPC1RAB9AALDH1A1HSD17B10
SCHEMBL1779174 0.83 RAB9A (0.39) KMT2ANPC1RAB9AALDH1A1HSD17B10
SCHEMBL1779425 0.83 MAPK1 (0.46) KMT2ANPC1RAB9AALDH1A1HSD17B10
SCHEMBL1779165 0.83 KDM4E (0.38) KMT2ARAB9AALDH1A1HSD17B10GAA
SCHEMBL3868186 0.82 KDR (0.42) KDRKMT2ANPC1RAB9AALDH1A1
SCHEMBL1780238 0.79 PTGER1 (0.39) KMT2ANPC1RAB9AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 KDR 814/4885KMT2A 2397/4885NPC1 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.